Lumiliximab

CAS No. 357613-86-6

Lumiliximab( —— )

Catalog No. M36903 CAS No. 357613-86-6

Lumiliximab (IDEC-152) is a primate-ized chimeric antibody targeting CD23 rhesus monkey/human chimeric antibody with inhibitory effects on IgE antibody production for the study of allergic diseases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 301 Get Quote
5MG 591 Get Quote
10MG 938 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Lumiliximab
  • Note
    Research use only, not for human use.
  • Brief Description
    Lumiliximab (IDEC-152) is a primate-ized chimeric antibody targeting CD23 rhesus monkey/human chimeric antibody with inhibitory effects on IgE antibody production for the study of allergic diseases.
  • Description
    Lumiliximab (Anti-CD23 Recombinant Antibody) is an anti-CD23 monoclonal antibody that inhibits allergen-induced responses.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    357613-86-6
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Poole JA, et al. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol. 2005 Oct;116(4):780-8.?
molnova catalog
related products
  • Imidacloprid-urea

    Imidacloprid-urea is a secondary metabolite of imidacloprid. Imidacloprid is a potent and widely used neonicotinoid with inhibitory effects on pests of cereals, vegetables, tea and cotton.

  • PS-47

    PS-47 is an inactive E-isomer of PS48. PS48 is an activator of PDK1.

  • Nimustine Hydrochlor...

    Nimustine has been used in trials studying the treatment of Glioblastoma.